https://www.prnewswire.com/news-releases/inmagene-and-kissei-enter-into-an-exclusive-license-agreement-for-fostamatinib-in-china-301345936.html
Inmagene and Kissei Enter into an Exclusive License Agreement for Fostamatinib in China
/PRNewswire/ -- Inmagene Biopharmaceuticals ("Inmagene") and Kissei Pharmaceutical Co., Ltd. ("Kissei") announced today that they have entered into an...
exclusive license agreement
https://www.fiercebiotech.com/biotech/kissei-pays-viridian-70m-challenge-amgen-japanese-eye-disease-market
Kissei pays Viridian $70M to challenge Amgen for Japanese market
Jul 30, 2025 - Kissei is paying $70 million upfront for Japanese rights to two thyroid eye disease assets, establishing the company as a potential rival to Amgen.
kisseipaysviridian70mchallenge